Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 183319-69-9
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: D/A,D/P,L/C,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
White Or Off-white Powder |
CAS NO:: |
183319-69-9 |
Molecular Formula:: |
C22H24ClN3O4 |
Molecular Weight:: |
429.89700 |
EINECS NO:: |
620-491-0 |
MDL NO:: |
MFCD07781272 |
Appearance:: |
White Or Off-white Powder |
CAS NO:: |
183319-69-9 |
Molecular Formula:: |
C22H24ClN3O4 |
Molecular Weight:: |
429.89700 |
EINECS NO:: |
620-491-0 |
MDL NO:: |
MFCD07781272 |
Product Description:
Product Name: Erlotinib hydrochloride CAS NO: 183319-69-9
Synonyms:
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride;
Tarceva;
OSI 774;
Chemical & Physical Properties:
Appearance: White or off-white powder
Assay :≥98.0%
Boiling Point: 553.6℃ at 760 mmHg
Melting Point: 223-225℃
Flash Point: 288.6℃
Vapor Pressure: 4.52E-12mmHg at 25℃
Storage Temp.: -20℃ Freezer
Safety Information:
HS Code: 2933990090
Erlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.
It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment.
Erlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.
